PriceTargets.com logo

Mainz Biomed - MYNZ Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.67
  • Forecasted Upside: 231.05%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.92 As of 09/29/2023 01:00 AM ET
▼ -0.15 (-4.89%)

This chart shows the closing price for MYNZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mainz Biomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYNZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYNZ

Analyst Price Target is $9.67
▲ +231.05% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Mainz Biomed in the last 3 months. The average price target is $9.67, with a high forecast of $11.00 and a low forecast of $9.00. The average price target represents a 231.05% upside from the last price of $2.92.

This chart shows the closing price for MYNZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Mainz Biomed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$9.00Low
9/22/2023HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $9.00Low
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$9.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$9.00Low
8/18/2023HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $7.00Low
5/18/2023Cantor FitzgeraldLower Target$15.00 ➝ $12.00Low
4/27/2023HC WainwrightLower Target$25.00 ➝ $10.00Low
3/30/2023HC WainwrightReiterated RatingBuy$25.00Low
2/16/2023HC WainwrightReiterated RatingBuy$25.00Low
2/10/2023JonestradingInitiated CoverageBuy$11.00Low
10/25/2022Cantor FitzgeraldInitiated CoverageOverweight$15.00Low
6/29/2022HC WainwrightReiterated RatingBuy$25.00Low
6/21/2022HC WainwrightInitiated CoverageBuy$25.00Low
(Data available from 9/30/2018 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 5 very negative mentions
Mentions as of
3/4/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
6/2/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 7 very negative mentions
Mentions as of
8/31/2023
  • 0 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Mainz Biomed logo
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.
Read More

Today's Range

Now: $2.92
Low: $2.90
High: $3.15

50 Day Range

MA: $3.45
Low: $2.90
High: $4.41

52 Week Range

Now: $2.92
Low: $2.84
High: $9.61

Volume

44,320 shs

Average Volume

305,142 shs

Market Capitalization

$35.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Mainz Biomed?

The following Wall Street sell-side analysts have issued stock ratings on Mainz Biomed in the last year: Cantor Fitzgerald, HC Wainwright, and Jonestrading.
View the latest analyst ratings for MYNZ.

What is the current price target for Mainz Biomed?

3 Wall Street analysts have set twelve-month price targets for Mainz Biomed in the last year. Their average twelve-month price target is $9.67, suggesting a possible upside of 231.1%. Jonestrading has the highest price target set, predicting MYNZ will reach $11.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $9.00 for Mainz Biomed in the next year.
View the latest price targets for MYNZ.

What is the current consensus analyst rating for Mainz Biomed?

Mainz Biomed currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MYNZ will outperform the market and that investors should add to their positions of Mainz Biomed.
View the latest ratings for MYNZ.

What other companies compete with Mainz Biomed?

Other companies that are similar to Mainz Biomed include Fortress Biotech, NextCure, Bolt Biotherapeutics, Lantern Pharma and Viracta Therapeutics. Learn More about companies similar to Mainz Biomed.

How do I contact Mainz Biomed's investor relations team?

The company's listed phone number is 49-6131-554-2860 and its investor relations email address is [email protected]. The official website for Mainz Biomed is mainzbiomed.com. Learn More about contacing Mainz Biomed investor relations.